A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective

Health Affairs

Volumn 30, Issue 2, 2011, Pages 340-348

  Post, Sarah E ^a   Sodhi, Neetu Khurana ^b   Peng, Chia Hui ^b   Wan, Kejia ^b   Pollack, Henry J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CALCULATION; COST EFFECTIVENESS ANALYSIS; DEATH; DISEASE COURSE; HEALTH CARE ACCESS; HEALTH CARE COST; HEPATITIS B; HIGH RISK POPULATION; LONG TERM CARE; OUTCOME ASSESSMENT; QUALITY OF LIFE; SCREENING TEST; SENSITIVITY ANALYSIS; SIMULATION; TREATMENT PLANNING;

ALGORITHMS; COMPREHENSIVE HEALTH CARE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE MANAGEMENT; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTH STATUS INDICATORS; HEPATITIS B, CHRONIC; INSURANCE COVERAGE; MARKOV CHAINS; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PREVENTIVE HEALTH SERVICES; PUBLIC HEALTH; QUALITY OF LIFE; UNITED STATES; VIRAL LOAD;

EID: 79955573541     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2008.0905     Document Type: Article

References (48)

1. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000;160(21):3227-30.
2. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int. 2005;25(4):696-703.
3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11(2):97-107.
4. Cohen C, Evans AA, London WT, Block J, Conti M, Block T. Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat. 2008; 15(1):12-3.
5. McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89(1):14-8.
6. Lok A, McMahon BJ. Chronic hepatitis B. Hepatology. 2001;34(6): 1225-41.
7. Gish RG, Gadan AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006;13(12): 787-98.
8. Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57(RR-8):1-20.
9. Dienstag JL, Goldin RD, Heathcote EJ, Hann HWL, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivu-dine therapy. Gastroenterology. 2003;124(1):105-17.
10. Lai CL, Rosmawati M, Lao J, Van Vlierberghe H, Anderson FH, Thomas N, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002;123(6):1831-8.
11. Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521-31.
12. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29(3): 971-5.
13. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808-16.
14. Rizzetto M, Tassopoulos NC, Goldin RD, Esteban R, Santantonio T, Heathcote EJ, et al. Extended lami-vudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005;42(2):173-9.
15. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocel-lular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1): 65-73.
16. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678-86.
17. Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, et al. Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol. 2004; 72(1):35-40.
18. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol. 2006;4(8):936-62.
19. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.
20. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW. Chronic viral hepatitis and hepatocellular carcinoma. World J Surg. 2007;31(6):1243-8.
21. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127(10):855-65.
22. Colvin HM, Mitchell AE, editors. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington (DC): National Academies Press; 2010.
23. Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion. J Viral Hepat. 2007;14(3):147-52.
24. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol. 2006; 101(9):2076-89.
25. Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology. 1983;84(2):216-9.
26. Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology. 1987;92(6): 1839-43.
27. Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, et al. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26(6): 680-7.
28. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipi-voxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess. 2006;10(28):iii-iv, xi-xiv, 1-183.
29. To access the Appendix, click on the Appendix link in the box to the right of the article online.
30. Pollack H, Sherman A, Tsang T, Wan K, Lupatkin H, Villanueva G, et al. Clinical characteristics of Asian Americans infected with hepatitis B diagnosed by community-based screenings in New York City [Abstract]. Hepatol. 2006;44:568A.
31. Pollack H, Wan K, Ramos R. Screening for chronic hepatitis B among Asian/Pacific Islander populations-New York City, 2005. MMWR Morbid Mortal Wkly Rep. 2006;55:505-9.
32. Arias E. United States life tables, 2004. Nat Vital Stat Rep. 2007; 56(9):1-39.
33. Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004; 2(2):87-106.
34. Berg T, Moller B, Trinh H, Chan S, Marcellin P, Suarez E, et al. Teno-fovir disoproxil fumarate (TDF) versus emtricitabine plus TDF for treatment of chronic hepatitis B (CHB) in subjects with persistent viral replication in receiving adefovir dipivoxil (ADV) [Internet]. Paper presented at: 44th Annual Meeting of the European Association for the Study of the Liver; 2009 Apr 22-26; Copenhagen, Denmark [cited 2010 May 30]. Available from: http://www.natap.org/2009/EASL/EASL_58.htm.
35. Heathcote J, Gane E, DeMan R, Lee S, Flisiak R, Manns M, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefo-vir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. Paper presented at: 58th Annual Meeting of the American Association for the Study of Liver Diseases; 2007 Nov 2-6; Boston, MA.
36. Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita K, Kotsev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-0102. Paper presented at: 58th Annual Meeting of the American Association for the Study of Liver Diseases; 2007 Nov 2-6; Boston, MA.
37. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003;348(9):808-16.
38. De Simone P, Vignali C, Petruccelli S, Carrai P, Coletti L, Montin U, et al. Cost analysis of tumor downsizing for hepatocellular carcinoma liver transplant candidates. Transplant Proc. 2006;38(10):3561-3.
39. Sarasin FP, Giostra E, Mentha G, Hadengue A. Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepato-cellular carcinoma? A cost-effectiveness perspective. Hepatology. 1998;28(2):436-42.
40. Patented Medicine Prices Review Board. Report on new patented drugs-Viread [Internet]. Ottawa (ON): PMPRB; 2004 [cited 2010 Dec 16]. Available from: http://www.pmprb-cepmb.gc.ca/english/View.asp?x=403&mp=572.
41. Centers for Medicare and Medicaid Services. State drug utilization data [Internet]. Baltimore (MD); CMS; 2006 [cited 2010 Dec 16]. Available from: https://www.cms.gov/MedicaidDrugRebateProgram/SDUD/list.asp.
42. Jing Y, Klein P, Kelton CM, Li X, Guo JJ. Utilization and spending trends for antiretroviral medications in the US Medicaid program from 1991 to 2005. AIDS Res Therapy. 2007;4:22.
43. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med. 1995;122(9): 664-75.
44. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996;276(15):1253-8.
45. Chong CA, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol. 2003; 98(3):630-8.
46. Hep B Free San Francisco. See a doctor who tests for hepatitis B [home page on the Internet]. San Francisco (CA): Community Initiatives Inc.; c2007-10 [cited 2009 Sep 21]. Available from: http://www.sfhepbfree.org/.
47. Hutton DW, Tan D, So SK, Brandeau ML. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med. 2007;147(7):460-9.
48. Lantz PM, Weisman CS, Itani Z. A disease-specific Medicaid expansion for women. The Breast and Cervical Cancer Prevention and Treatment Act of 2000. Womens Health Issues. 2003;13(3):79-92.